Nicotine Patch, Blood Flow and Oxidative Stress Study

University of Pennsylvania

Status: Completed

Conditions: Healthy

Treatments: Drug: transdermal nicotine patch (7mg)

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00954096

707275

0875

Details and patient eligibility

About

This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

Full description

Smoking causes >400,000 deaths from cardiovascular disease (CVD) per year. The molecular basis of smoking induced tissue injury remains unclear but considerable evidence supports a role for oxidant stress (OS).

Arterial function has been shown to be impaired in smokers even before the onset of angiographically demonstrable atherosclerosis. Defects in endothelium dependant flow mediated vasodilatation (FMD) are seen in those at risk of or with overt vascular disease.

Cigarette smoking is highly addictive. Spontaneous quit rates approximate 3%. Even those using nicotine replacement therapy (NRT) have high relapse rates (67-75%) on completion of the 8-12 week course of NRT. Thus there is interest in the use of extended NRT as a "safer" alternative to cigarette smoking. However such assumptions may be premature. Nicotine demonstrates proxidant effects in vitro and in small studies has been associated with endothelial dysfunction. Studies simultaneously assessing the effects of nicotine on oxidative stress and arterial function in humans have not been performed.

The current proposal will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.

Enrollment: 55 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy individuals
• Nonsmokers who have never smoked
• Normal medical history
• Normal physical examination
• Normal laboratory data
• Negative urinary pregnancy test for females

Exclusion criteria

• Previous CVD
• Chronic medication use
• History alcoholism
• History of smoking
• Current pregnancy
• Subjects, who have less than or equal to 60% platelet aggregation in response to arachidonic acid will also be excluded.

Trial design

55 participants in 1 patient group

Transdermal nicotine patch or placebo

Experimental group

Description:

A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.

Treatment:

Drug: transdermal nicotine patch (7mg)